R3 Asset Management Pte

Axonis Therapeutics is a biotechnology company focused on developing therapies for neurological disorders by targeting the KCC2, a key mediator of inhibition in the brain. The company leverages groundbreaking research from institutions such as Boston Children’s Hospital, Harvard, and Laval University to create a proprietary neuron-specific K-Cl cotransporter discovery engine. This innovative platform aims to enhance the treatment of various conditions, including epilepsy, pain, and other central nervous system pathologies, by fine-tuning neuronal inhibition. Through its efforts, Axonis Therapeutics seeks to contribute to the healthcare industry's ability to combat neurodegeneration, restore neuronal excitation, and promote neuron regeneration, ultimately improving the quality of life for individuals affected by these disorders.

Vividthree Productions Pte. Ltd. is a prominent company based in Singapore that specializes in motion picture post-production, visual effects (VFX), and 3D animation. Founded in 2004, the company has established itself as a leading studio in the realms of multimedia and interactive design, offering services that include three-dimensional animation and computer-generated imagery (CGI). It has developed a strong reputation and network presence in Singapore, Malaysia, and China, positioning itself as a go-to studio for immersive digital content production. Vividthree Productions operates as a subsidiary of mm2 Entertainment Pte. Ltd. and continues to contribute significantly to the visual effects and animation industries in the region.